Kiran Mazumdar Shaw Redesignated As Executive Chairperson Of Syngene International; Siddharth Mittal Appointed As CEO & MD

Kiran Mazumdar Shaw has been redesignated from Non-Executive Chairperson to Executive Chairperson and a Key Managerial Personnel (KMP) of Syngene International Limited, effective April 1, 2026, subject to the approval of the shareholders.

Further, Siddharth Mittal has been appointed as Chief Executive Officer and Managing Director (CEO & MD) of the company and a member of the Executive Committee, effective July 1, 2026, subject to the approval of the shareholders. He will succeed Peter Bains, who has resigned and will step down effective June 30, 2026.

Mazumdar-Shaw is the Executive Chairperson and Founder of Biocon Group. She has over four decades of experience in biotechnology and has led the company since its founding in 1978. Under her leadership, Biocon has expanded into a biopharmaceutical enterprise with operations across global markets, focusing on research, manufacturing, and healthcare solutions. She has received national honours, including the Padma Shri and Padma Bhushan. Mazumdar-Shaw has been involved in roles across industry, academia, and policy platforms. Her work includes contributions to healthcare, research, and innovation initiatives through various organisations and advisory roles.

Mittal previously served as CEO & MD of Biocon Ltd. He joined the company in May 2013 and was president and chief financial officer until November 2019. He has over two decades of experience in finance, mergers and acquisitions (M&A), and general management. During his tenure, he worked on the development of the biosimilars business and its transition into Biocon Biologics in 2019. He also led the company’s entry into the generic formulations segment, building a portfolio across markets. His work included expansion into areas such as peptides and GLP-1 therapies as part of the company’s product development and growth plans.

Bains has held leadership roles across global organisations, including serving as CEO of Sosei Group, now known as Nxera Pharma. Earlier, he worked with GlaxoSmithKline for over two decades in roles such as Head of Global Marketing and Senior Vice President (SVP) for International Regions. He previously served as chief executive officer and board member at Syngene, where he led the company through its public listing in 2015. He has over three decades of experience in the pharmaceutical and biotechnology sectors. At Syngene International, he is responsible for strategy, investment decisions, and business operations. Bains holds a degree in zoology and physiology from the University of Sheffield.